Prognostic Factors and the Impact of Adjuvant Therapy on Survival Outcomes in ypT0-2N0M0 Oesophageal Squamous Cell Carcinoma
European Journal of Cardio-Thoracic Surgery · 01.04.2026 · 68 (4)
DOI: 10.1093/ejcts/ezag039 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cardio-Thoracic Surgery, online erschienen am 28.03.2026. Verfasst von Soraya Agouzzal und 11 weiteren Autor:innen. Beteiligte Einrichtung: West China School of Medicine, Sichuan University, Chengdu 610041, China. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Esophagectomy. Die Arbeit nennt 24 Literaturangaben. Gefördert von: "Qimingxing" Research Fund for Young Talents, West China Hospital, “Qimingxing” Research Fund for Young Talents, West China Hospital.
Abstract (Originalsprache)
Objectives
The role of adjuvant therapy in ypT0-2N0M0 oesophageal squamous cell carcinoma (OSCC) remains controversial. This study aimed to assess the impact of adjuvant therapy on overall survival (OS) and disease-free survival (DFS) and to develop prognostic nomogram models.
Methods
Patients with ypT0-2N0M0 followed by radical oesophagectomy between 2011 and 2024 were reviewed. Propensity score matching (PSM) was applied to adjust for baseline imbalances between treatment groups. OS and DFS were estimated using the Kaplan–Meier method. Prognostic factors were evaluated using the Cox proportional hazards model, and nomogram models were developed.
Results
A total of 363 patients were enrolled in the study, of whom 67 received adjuvant therapy. Patients who received adjuvant therapy had significantly poorer OS and DFS compared with those who did not, both before and after PSM (P < .05). Multivariate analyses identified adjuvant therapy as an independent adverse prognostic factor for OS and DFS (P < .05). The nomogram demonstrated good discrimination for OS, with time-dependent areas under the receiver operating characteristic curve (AUCs) of 0.729 (95% CI, 0.623-0.835) and 0.716 (95% CI, 0.642-0.790) at 1 and 3 years, respectively, and acceptable discrimination for DFS, with corresponding AUCs of 0.673 (95% CI, 0.596-0.751) and 0.659 (95% CI, 0.589-0.728).
Conclusions
In patients with ypT0-2N0M0 OSCC, adjuvant therapy may not be associated with improved OS or DFS. The developed nomogram models demonstrated good performance in predicting individualized OS and DFS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- West China School of Medicine, Sichuan University, Chengdu 610041, China.
- Department of Thoracic Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, China.
- Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
- Department of Surgery, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.
ORCID-Profile: Long-Qi Chen, Dong Tian
Förderung
- "Qimingxing" Research Fund for Young Talents, West China Hospital
- “Qimingxing” Research Fund for Young Talents, West China Hospital
Zitieren
APA
Agouzzal, S., Abraham, S. H., Wang, J. J., Liu, S. X., Xia, B. Y., Wang, L., Li, J., Yuan, P. S., Li, K. D., Chen, L. Q., Jiang, K. Y., & Tian, D. (2026). Prognostic Factors and the Impact of Adjuvant Therapy on Survival Outcomes in ypT0-2N0M0 Oesophageal Squamous Cell Carcinoma. European Journal of Cardio-Thoracic Surgery, 68(4). https://doi.org/10.1093/ejcts/ezag039
Vancouver
Agouzzal S, Abraham SH, Wang JJ, Liu SX, Xia BY, Wang L, et al. Prognostic Factors and the Impact of Adjuvant Therapy on Survival Outcomes in ypT0-2N0M0 Oesophageal Squamous Cell Carcinoma. European Journal of Cardio-Thoracic Surgery. 2026;68(4). doi:10.1093/ejcts/ezag039
BibTeX
@article{Agouzzal2026,
author = {Agouzzal, Soraya and Abraham, Sharon Hannah and Wang, Jun-Jie and Liu, Shi-Xiang and Xia, Bo-Yang and Wang, Lei and Li, Jie and Yuan, Pei-Song and Li, Kai-Di and Chen, Long-Qi and Jiang, Kai-Yuan and Tian, Dong},
title = {Prognostic Factors and the Impact of Adjuvant Therapy on Survival Outcomes in ypT0-2N0M0 Oesophageal Squamous Cell Carcinoma},
journal = {European Journal of Cardio-Thoracic Surgery},
year = {2026},
volume = {68},
number = {4},
doi = {10.1093/ejcts/ezag039}
}
EUVIMED